Understanding chronic inflammation

When tissues are injured or exposed to pathogens, the immune system launches a rapid inflammatory response. Blood vessels widen, blood flow increases, and immune cells travel to the site, guided by signalling proteins called cytokines.

Once the threat is controlled, the body enters an active resolution phase involving specialised pro-resolving mediators (SPMs) to clear cellular debris and repair tissue. Healthy immune function relies on this complete cycle, not on permanently eliminating all inflammatory signals.

Acute inflammation resolves once healing is underway. In contrast, chronic inflammation persists for months or years. It can be localised, as in an inflamed joint or bowel, or low-grade and systemic across multiple tissues.

Chronic inflammation is a biological process rather than a single diagnosis. Rheumatoid arthritis, asthma, inflammatory bowel disease and metabolic inflammation have different triggers and require distinct clinical approaches.

Fat tissue is an active endocrine organ. Under sustained nutrient excess, fat cells experience cellular stress and recruit immune cells. Visceral fat surrounding abdominal organs is particularly prone to releasing inflammatory cytokines.

This creates a bidirectional feedback loop: metabolic strain promotes inflammation, and inflammatory signals impair insulin sensitivity in muscle and liver tissue. Improving metabolic health can reduce a major systemic inflammatory driver.

Persistent bacterial or viral infections can maintain immune activation. In autoimmune conditions, such as rheumatoid arthritis or type 1 diabetes, the immune system mistakenly attacks healthy tissue. In asthma, sensitive airways react to allergens and irritants.

Easily overlooked sources of chronic low-grade inflammation include periodontal (gum) disease, untreated obstructive sleep apnoea and prolonged psychological stress. Regular dental care and treating sleep apnoea directly remove active inflammatory drivers.

In blood vessels, persistent inflammation participates in atherosclerosis, contributing to plaque growth and instability. Managing cardiovascular risk requires addressing inflammation alongside blood pressure, LDL cholesterol, blood sugar and smoking.

In the liver, metabolic inflammation can drive the progression from simple fat accumulation to metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis. Long-standing chronic inflammation in the joints (such as rheumatoid arthritis) or the digestive tract (Crohn's disease, ulcerative colitis) can cause progressive structural damage if not treated effectively.

Long-standing chronic inflammatory conditions in specific organs can increase the risk of certain cancers, such as colorectal cancer in severe chronic inflammatory bowel disease. However, an elevated inflammatory marker does not mean a person has or will develop cancer.

Ageing is frequently accompanied by a shift towards low-grade systemic inflammation, termed 'inflammaging'. Cellular senescence and mitochondrial DNA release are active areas of research, though experimental findings in animals do not establish that consumer longevity products reverse human ageing.

C-reactive protein (CRP) is produced by the liver in response to inflammatory cytokines. High-sensitivity CRP (hs-CRP) measures lower concentrations and helps evaluate cardiovascular risk.

However, CRP is non-specific: a temporary rise can result from a mild viral infection or physical injury. Normal CRP levels do not rule out all localised inflammatory conditions. Comprehensive assessment includes clinical history, physical exams, imaging and disease-specific biomarkers.

A nutrient-dense, Mediterranean-style dietary pattern rich in vegetables, legumes, berries, nuts, olive oil and quality protein provides a strong foundation. Minimising ultra-processed foods, excess refined sugars and industrial trans fats reduces sustained metabolic strain.

Fasting and time-restricted eating can alter inflammatory pathways, but fasting is optional and must be adapted safely for individuals taking glucose-lowering medications or managing specific medical conditions.

Regular physical activity helps lower systemic inflammatory markers over time and improves insulin sensitivity. A balanced routine combines moderate aerobic activity with resistance training.

Intense exercise triggers a temporary, beneficial acute inflammatory response necessary for adaptation. Adequate recovery, nutrition and sleep ensure this acute response does not become chronic fatigue or joint overload.

Most adults benefit from 7 to 9 hours of quality sleep. Chronic sleep deprivation and unmanaged psychological stress reduce glucocorticoid receptor sensitivity and elevate inflammatory signalling.

Mindfulness, structured rest and professional support improve coping and daily function, though lifestyle measures work best alongside—not in place of—medical treatment for diagnosed inflammatory diseases.

When chronic inflammation stems from autoimmune or chronic disease, targeted medical care is essential. Disease-modifying antirheumatic drugs (DMARDs), biologics, corticosteroids and targeted therapies help prevent long-term organ and joint damage.

Non-steroidal anti-inflammatory drugs (NSAIDs) relieve acute symptoms but carry gastrointestinal, renal and cardiovascular risks with long-term unsupervised use. The landmark CANTOS trial demonstrated that targeting specific inflammatory pathways reduces cardiovascular events, but also highlighted the trade-off of increased infection risk.

Omega-3 fatty acids (EPA/DHA) serve as substrates for specialised pro-resolving mediators and can modestly support joint comfort and lipid balance. Check actual EPA and DHA amounts per serving.

Curcumin has been widely studied for joint discomfort in osteoarthritis; bioavailability varies significantly between formulations, and high-absorption products require attention to liver safety and drug interactions. Vitamin D, magnesium and ashwagandha can support specific physiological needs but do not constitute broad anti-inflammatory cures.

Methylene blue and NAD precursors (NR, NMN) are actively investigated for mitochondrial energetics and cellular stress responses. While mechanistic and animal findings are compelling, they remain research-stage metabolic tools and should not be used as unmonitored treatments for autoimmune or inflammatory conditions. Methylene blue carries serious risks of serotonin syndrome when combined with serotonergic medications.

Research peptides such as BPC-157, TB-500 and MOTS-c lack robust human clinical trial data for chronic systemic inflammation and carry regulatory and purity concerns. They should not replace approved medical care.

Consumer recovery tools can support daily habits and local comfort. Photobiomodulation (red and near-infrared light panels or wraps) and PEMF mats have shown modest benefits in selected localised pain conditions, though study parameters vary.

Cold-water immersion (ice baths) may reduce perceived muscle soreness, but regular post-workout cold plunges can blunt muscular adaptations from resistance training. Gentle heat, massage tools, verified HEPA air purifiers and hydrogen-rich water offer optional comfort and routine support within their verified technical specifications.

Seek immediate medical attention for sudden chest pain, stroke symptoms, severe shortness of breath, high fever with confusion, or a hot, severely swollen joint accompanied by systemic illness.

This article provides general health education and is not a substitute for clinical diagnosis, prescription or personalised medical treatment. Individuals with autoimmune conditions, cardiovascular disease or ongoing medication regimens should consult their physician before making treatment changes.

Never stop prescribed anti-inflammatory or disease-modifying medication without medical supervision.